FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to application of transcript modifying agents to prevent the genetic grading of malignant cells required to resist cell damage and their survival in chemotherapy or radiotherapy. There is applied a pharmaceutical composition containing hydralazine and valproic acid or its salt, e.g. magnesium valproate, in a pharmaceutically acceptable carrier to assist in cancer treatment along with chemotherapy or radiotherapy.
EFFECT: invention provides synergetic effect in cancer treatment by conventional therapeutic agents.
5 cl, 5 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| HYSTONE DESACETYLASE INHIBITORS FROM NOVEL BENZAMIDE DERIVATIVES WITH STRONG DIFFERENTIAL ANTI-PROLOFERATIVE ACTIVITY | 2004 |
|
RU2364589C2 |
| METHOD OF PRODUCING OF PLURIPOTENT STEM CELLS | 2014 |
|
RU2565548C1 |
| METHOD OF FINAL DIFFERENTIATION INDUCTION | 2010 |
|
RU2530648C2 |
| SYSTEMS, METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2012 |
|
RU2644635C2 |
| METHOD OF INDUCING TERMINAL DIFFERENTIATION | 2003 |
|
RU2394022C2 |
| METHODS FOR COMBINATION THERAPY OF PROLIFERATIVE DISEASES | 2011 |
|
RU2577278C2 |
| METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION | 2003 |
|
RU2320331C2 |
| METHOD OF PREDICTING EFFICIENCY OF RAR-α AGONIST | 2006 |
|
RU2405447C2 |
